TransMedics Group remains a hold-rated stock as its Organ Care System technology drives adoption and first-quarter 2026 results show solid case volume growth, though gross margin pressure persists. The company's OCS is the only FDA-approved portable platform offering warm perfusion for heart, lung, and liver transplants, positioning it as a leader in the multi-billion-dollar transplant market. TransMedics is advancing next-generation OCS systems and expanding into kidney transplantation, with a U.S. IDE submission targeted for early 2027. First-quarter gross margin fell 331 basis points year over year to approximately 58%, weighed by investments in clinical programs and lower-margin logistics revenue. The Zacks Consensus Estimate for 2026 earnings has been revised down by 3 cents to $1.87 per share over the past 30 days.
Globus Medical
Intuitive Surgical IncTransMedics Group IncOCS technology drives adoption and next-gen systems advancing, but margin pressure and earnings estimate cut create mixed outlook
West Pharmaceutical Services Inc